Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DNDi 6899

Next Previous
Drug Profile

DNDi 6899

Alternative Names: Compund 7 - GSK/University of Dundee; DDD-853651; DNDi-6899; GSK-3186899; GSK-899

Latest Information Update: 27 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; University of Dundee
  • Developer GSK
  • Class 2 ring heterocyclic compounds; Amines; Antiprotozoals; Cyclohexanes; Fluorinated hydrocarbons; Morpholines; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Leishmaniasis

Most Recent Events

  • 27 Sep 2024 Discontinued - Phase-I for Leishmaniasis (In volunteers) in United Kingdom (PO) (Drugs for Neglected Diseases Initiative Foundation website, March 2024)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Leishmaniasis(In volunteers) in United Kingdom (PO, Suspension)
  • 02 Aug 2022 GSK 3186899 is still in phase I trials for Leishmaniasis in United Kingdom (GlaxoSmithKline pipeline, August 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top